Kronos Bio (KRON)
(Delayed Data from NSDQ)
$0.99 USD
0.00 (0.11%)
Updated Aug 15, 2024 04:00 PM ET
After-Market: $0.98 -0.01 (-0.77%) 7:58 PM ET
2-Buy of 5 2
F Value B Growth C Momentum D VGM
Price, Consensus and EPS Surprise
KRON 0.99 0.00(0.11%)
Will KRON be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for KRON based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for KRON
10x Genomics (TXG) Reports Q2 Loss, Tops Revenue Estimates
CureVac N.V. (CVAC) Expected to Beat Earnings Estimates: Should You Buy?
KRON: What are Zacks experts saying now?
Zacks Private Portfolio Services
AbCellera Biologics Inc. (ABCL) Reports Q2 Loss, Misses Revenue Estimates
Kronos Bio, Inc. (KRON) Expected to Beat Earnings Estimates: Should You Buy?
Down -5.63% in 4 Weeks, Here's Why Kronos Bio (KRON) Looks Ripe for a Turnaround
Other News for KRON
Piper Sandler Sticks to Their Buy Rating for Kronos Bio (KRON)
KRON Stock Earnings: Kronos Bio Beats EPS, Beats Revenue for Q2 2024
Kronos Bio GAAP EPS of -$0.27, revenue of $2.69M
Kronos Bio Reports Second Quarter 2024 Financial Results and Pipeline Update
Buy Rating Affirmed for Kronos Bio Amid Promising Clinical Developments and Strategic Expansion